Voxar's latest 3D version 4.2 has been integrated into Agfa's PACS solution, Impax. The integration is the result of a global distribution agreement that Agfa and Voxar signed late last year. The new software allows PET visualization and simultaneous
Voxar's latest 3D version 4.2 has been integrated into Agfa's PACS solution, Impax. The integration is the result of a global distribution agreement that Agfa and Voxar signed late last year. The new software allows PET visualization and simultaneous comparison of PET and CT images, as well as state-of-the-art image enhancement and measurement tools. One-click processes allow 2D, 3D, maximum-intensity projection, and multiplanar reconstruction. Automatic MPR Shape Selection enables selection, measurement, and display of complex heterogeneous structures. Protected health information is stripped from DICOM images using features integral to the application.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.